486 related articles for article (PubMed ID: 32371139)
21. Are nanotheranostics and nanodiagnostics-guided drug delivery stepping stones towards precision medicine?
Blau R; Krivitsky A; Epshtein Y; Satchi-Fainaro R
Drug Resist Updat; 2016 Jul; 27():39-58. PubMed ID: 27449597
[TBL] [Abstract][Full Text] [Related]
22. Advanced drug-delivery systems: mechanoresponsive nanoplatforms applicable in atherosclerosis management.
Nurhidayah D; Maruf A; Zhang X; Liao X; Wu W; Wang G
Nanomedicine (Lond); 2019 Dec; 14(23):3105-3122. PubMed ID: 31823682
[TBL] [Abstract][Full Text] [Related]
23. Magnetic nanoparticles based cancer therapy: current status and applications.
Zhang H; Liu XL; Zhang YF; Gao F; Li GL; He Y; Peng ML; Fan HM
Sci China Life Sci; 2018 Apr; 61(4):400-414. PubMed ID: 29675551
[TBL] [Abstract][Full Text] [Related]
24. Ligand-Installed Nanocarriers toward Precision Therapy.
Mi P; Cabral H; Kataoka K
Adv Mater; 2020 Apr; 32(13):e1902604. PubMed ID: 31353770
[TBL] [Abstract][Full Text] [Related]
25. Advances in refunctionalization of erythrocyte-based nanomedicine for enhancing cancer-targeted drug delivery.
Sun D; Chen J; Wang Y; Ji H; Peng R; Jin L; Wu W
Theranostics; 2019; 9(23):6885-6900. PubMed ID: 31660075
[TBL] [Abstract][Full Text] [Related]
26. Nanotheranostic Pluronic-Like Polymeric Micelles: Shedding Light into the Dark Shadows of Tumors.
Domingues C; Alvarez-Lorenzo C; Concheiro A; Veiga F; Figueiras A
Mol Pharm; 2019 Dec; 16(12):4757-4774. PubMed ID: 31633939
[TBL] [Abstract][Full Text] [Related]
27. Using Peptide Aptamer Targeted Polymers as a Model Nanomedicine for Investigating Drug Distribution in Cancer Nanotheranostics.
Zhao Y; Houston ZH; Simpson JD; Chen L; Fletcher NL; Fuchs AV; Blakey I; Thurecht KJ
Mol Pharm; 2017 Oct; 14(10):3539-3549. PubMed ID: 28880092
[TBL] [Abstract][Full Text] [Related]
28. Nanoparticle-based theranostic agents.
Xie J; Lee S; Chen X
Adv Drug Deliv Rev; 2010 Aug; 62(11):1064-79. PubMed ID: 20691229
[TBL] [Abstract][Full Text] [Related]
29. Theranostic barcoded nanoparticles for personalized cancer medicine.
Yaari Z; da Silva D; Zinger A; Goldman E; Kajal A; Tshuva R; Barak E; Dahan N; Hershkovitz D; Goldfeder M; Roitman JS; Schroeder A
Nat Commun; 2016 Nov; 7():13325. PubMed ID: 27830705
[TBL] [Abstract][Full Text] [Related]
30. Theranostics Nanomedicine Applications for Colorectal Cancer and Metastasis: Recent Advances.
Kasi PB; Mallela VR; Ambrozkiewicz F; Trailin A; Liška V; Hemminki K
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175627
[TBL] [Abstract][Full Text] [Related]
31. Magnetic nanoparticles for precision oncology: theranostic magnetic iron oxide nanoparticles for image-guided and targeted cancer therapy.
Zhu L; Zhou Z; Mao H; Yang L
Nanomedicine (Lond); 2017 Jan; 12(1):73-87. PubMed ID: 27876448
[TBL] [Abstract][Full Text] [Related]
32. Recent advances in "smart" delivery systems for extended drug release in cancer therapy.
Kalaydina RV; Bajwa K; Qorri B; Decarlo A; Szewczuk MR
Int J Nanomedicine; 2018; 13():4727-4745. PubMed ID: 30154657
[TBL] [Abstract][Full Text] [Related]
33. Targetable Clinical Nanoparticles for Precision Cancer Therapy Based on Disease-Specific Molecular Inflection Points.
Kaittanis C; Bolaender A; Yoo B; Shah N; Ouerfelli O; Grimm J
Nano Lett; 2017 Nov; 17(11):7160-7168. PubMed ID: 29035540
[TBL] [Abstract][Full Text] [Related]
34. Biomedical application of graphene: From drug delivery, tumor therapy, to theranostics.
Song S; Shen H; Wang Y; Chu X; Xie J; Zhou N; Shen J
Colloids Surf B Biointerfaces; 2020 Jan; 185():110596. PubMed ID: 31707226
[TBL] [Abstract][Full Text] [Related]
35. Prodrugs in combination with nanocarriers as a strategy for promoting antitumoral efficiency.
Lin MH; Hung CF; Hsu CY; Lin ZC; Fang JY
Future Med Chem; 2019 Aug; 11(16):2131-2150. PubMed ID: 31538520
[TBL] [Abstract][Full Text] [Related]
36. Dendrimer Architectonics to Treat Cancer and Neurodegenerative Diseases with Implications in Theranostics and Personalized Medicine.
Moorthy H; Govindaraju T
ACS Appl Bio Mater; 2021 Feb; 4(2):1115-1139. PubMed ID: 35014470
[TBL] [Abstract][Full Text] [Related]
37. Zeolites for theranostic applications.
Khodadadi Yazdi M; Zarrintaj P; Hosseiniamoli H; Mashhadzadeh AH; Saeb MR; Ramsey JD; Ganjali MR; Mozafari M
J Mater Chem B; 2020 Jul; 8(28):5992-6012. PubMed ID: 32602516
[TBL] [Abstract][Full Text] [Related]
38. Immune Cell-Mediated Biodegradable Theranostic Nanoparticles for Melanoma Targeting and Drug Delivery.
Xie Z; Su Y; Kim GB; Selvi E; Ma C; Aragon-Sanabria V; Hsieh JT; Dong C; Yang J
Small; 2017 Mar; 13(10):. PubMed ID: 28026115
[TBL] [Abstract][Full Text] [Related]
39. Potential drug delivery nanosystems for improving tumor penetration.
Peng F; Li R; Zhang F; Qin L; Ling G; Zhang P
Eur J Pharm Biopharm; 2020 Jun; 151():220-238. PubMed ID: 32311427
[TBL] [Abstract][Full Text] [Related]
40. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
